hotspot -WSS

hotspot

author：focus 2025-09-30 19:26:10 - browse：1527

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Long Covid research funding gets a major boost from NIH

Wikipedia

WSS

Abbott's new heart device gets FDA advisory panel nod

Too many hospitalized Covid

Abbott's new heart device gets FDA advisory panel nod

Top private equity targets in 2023: cardiology, clinical trials, lasers

Too many hospitalized Covid

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

hotspot

explore

Heart attack and stroke risk calculators need revising

Why Eli Lilly’s earnings didn’t quite live up to the hype

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Drug repurposing or repositioning? The language matters

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medical leaders decry Supreme Court decision on affirmative action

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why Eli Lilly’s earnings didn’t quite live up to the hype

focus

AI gets buy

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Congress might make insulin pumps more accessible to the blind

ACIP vaccine advisory panel sees its vacancies filled

STAT Boddities: What happens to the brain when we get scared?

Devoted Health’s losses in Medicare Advantage persist

Wikipedia

Wikipedia

leisure time

explore